BDTX - Black Diamond Therapeutics, Inc. News

Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.17) per share which beat th

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Upda

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),

seekingalpha.com

Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in pre

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality w

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profi

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and do

feeds.benzinga.com

What's Going On With Black Diamond Therapeutics Stock Tuesday?

Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving av

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS act

12 Health Care Stocks Moving In Friday's Intraday Session

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),

marketbeat.com

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Pa

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 T

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and cont

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updat

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including prelimin

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

Investors need to pay close attention to BDTX stock based on the movements in the options market lat

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and d

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistanc

Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks

BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signa

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGF

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX)

Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?

BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026

BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblasto

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Tuesday's After-Market Session

10 Health Care Stocks Whale Activity In Today's Session

Nanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday's Pre-Market Sessio

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pr

$3 Million Bet On Taysha Gene Therapies? Check Out These 3 Penny Stocks Insiders Are Buying

The Dow Jones closed lower by more than 500 points on Wednesday. Investors, meanwhile, focused on so

During Wednesday's trading, 517 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 838 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

During Monday's trading, 528 companies set new 52-week lows.

On Wednesday, 215 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 540 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

On Monday, 149 companies reached new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

During Wednesday's trading, 435 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 211 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

During Thursday, 849 stocks hit new 52-week lows.

Wednesday's session saw 784 companies set new 52-week lows.

53 Biggest Movers From Yesterday

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday.

Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022

Upgrades

Wednesday's session saw 107 companies set new 52-week lows.

On Wednesday, 348 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

During Friday's session, 445 companies made new 52-week lows.

70 Biggest Movers From Yesterday

Gainers CPS Technologies Corporation (NASDAQ: CPSH) shares climbed 113.8% to close at $6.84 on Tu